Alder BioPharmaceuticals Announces Closing of $250M of 2.50% Convertible Senior Notes Due 2025 Post author:Sam Post published:February 1, 2018 Post category:BioPharma Alder intends to use the cash to fund the development and commercialization of eptinezumab. Source: BioSpace You Might Also Like SAGE Therapeutics Announces Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update February 22, 2017 Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Trea… November 9, 2017 How Eli Lilly Allegedly Used a Fake Rule and Fake News to Protect Bad Patents August 15, 2017
SAGE Therapeutics Announces Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update February 22, 2017
Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Trea… November 9, 2017